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 ABSTRACT 
Bone mass and mechanical properties are known to influence risk of fragility fracture. 
Clinical measures of bone mineral density (BMD) are used to evaluate fracture risk, but patients 
with obesity have greater risk of fracture than would be expected from BMD. Obesity is a 
common component of metabolic syndrome. Metabolic syndrome may contribute to the 
increased risk of fracture associated with obesity. Patients with osteoporosis have low bone mass 
and increased risk of fracture. Parathyroid hormone (PTH) treatment can be used to reverse the 
effects of osteoporosis. Here, we looked at mechanical properties of bone in an animal model of 
metabolic syndrome and an animal model of osteoporosis treated with parathyroid hormone.  
First, we characterized the cortical bone phenotype of the toll-like receptor 5 deficient 
mouse (TLR5KO). The TLR5KO mouse is a model of metabolic syndrome with mild levels of 
adiposity. Metabolic syndrome in TLR5KO mice is caused by alterations to the gut microbiome. 
Male and female mice 10-55 weeks of age (n = 5-19/ group) were used in this study. Cortical 
bone geometry and mechanical properties of the mid-diaphysis of the femur were analyzed to 
characterize the cortical bone phenotype. The femurs were tested in three-point bending to obtain 
peak moment, bending rigidity and post yield displacement. Peak moment was related to 
geometry to infer the effect of genotype on tissue material properties. We found that metabolic 
syndrome was associated with impaired cortical bone tissue material properties in both male and 
female mice in most ages studied. In summary, metabolic syndrome with only mild adiposity 
was associated with alterations to bone strength that could not be explained by bone geometry 
and density, suggesting altered bone tissue material properties.  
Secondly, we determined the mechanical properties of cancellous bone from osteopenic 
sheep treated with PTH. Osteopenia was induced in 6-7 year-old sheep through a combination of 
ovariectomy (OVX) and a diet to induce metabolic acidosis (MA). A year after OVX, the sheep 
   
were treated with either vehicle (n = 6) or PTH (n = 7) for a year. Cancellous bone cores were 
taken from the medial caudal quadrant of the right distal femur for mechanical testing. We found 
no detectable effect of PTH treatment on mechanical properties of cancellous bone in uniaxial 
compression.
iii 
 
BIOGRAPHICAL SKETCH 
  
Remy Elisabeth Walk was born in Wynnewood, Pennsylvania in 1992. She graduated from The 
Baldwin School in 2011. In 2015, she graduated cum laude from Cornell University in Ithaca, 
New York with a Bachelor of Science degree in Mechanical Engineering.   
iv 
 
ACKNOWLEDGMENTS 
I would like to thank my friends and family for their support and encouragement. I would also 
like to thank my graduate advisory committee for their help and guidance.  In addition, the 
advice and assistance of the entire Hernandez Lab was invaluable in the completion of this 
thesis.
v 
 
TABLE OF CONTENTS 
 
BIOGRAPHICAL SKETCH ....................................................................................................................... iii 
ACKNOWLEDGMENTS ............................................................................................................................ iv 
CHAPTER 1 .................................................................................................................................................. 1 
INTRODUCTION ......................................................................................................................................... 1 
1.1 Bone ..................................................................................................................................................... 1 
1.2 Fragility Fracture and Whole Bone Mechanical Properties ................................................................. 2 
1.3 Bone Growth and Development .......................................................................................................... 3 
1.4 Understanding Fracture Risk ............................................................................................................... 4 
1.4.1 Mechanical Properties of Cortical Bone ....................................................................................... 4 
1.4.2 Mechanical Properties of Cancellous Bone .................................................................................. 6 
1.5 Obesity and Bone ................................................................................................................................. 7 
1.6 Osteoporosis and PTH Therapy ........................................................................................................... 7 
1.7 Objective .............................................................................................................................................. 8 
1.7.1 Aim 1 ............................................................................................................................................. 8 
1.7.2 Aim 2 ............................................................................................................................................. 9 
REFERENCES ............................................................................................................................................. 10 
CHAPTER 2 ................................................................................................................................................ 13 
BONE PHENOTYPE OF THE TOLL-LIKE RECEPTOR FIVE DEFICIENT MOUSE .......................... 13 
2.1 Introduction ....................................................................................................................................... 13 
2.2 Material and Methods ....................................................................................................................... 16 
2.2.1 Cortical bone mechanical testing ............................................................................................... 16 
2.2.2 Statistical Analyses...................................................................................................................... 18 
2.3 Results ................................................................................................................................................ 18 
2.3.1 TLR5KO genotype........................................................................................................................ 18 
 ............................................................................................................................................................. 20 
2.3.2 Whole bone mechanical performance ....................................................................................... 20 
2.3.3 Femoral cross-sectional geometry ............................................................................................. 23 
2.3.4 Mechanical performance ................................................................................................................ 26 
2.4 Discussion .......................................................................................................................................... 28 
vi 
 
REFERENCES ............................................................................................................................................. 32 
CHAPTER 3 ................................................................................................................................................ 37 
EFFECT OF PTH-TREATMENT ON MECHANICAL PROPERTIES OF CANCELLOUS BONE ...... 37 
3.1 Introduction ....................................................................................................................................... 37 
3.2 Materials and methods ...................................................................................................................... 38 
3.2.1 Sample preparation .................................................................................................................... 38 
3.2.2 Mechanical testing ...................................................................................................................... 38 
3.2.3 Microcomputed Tomography ..................................................................................................... 39 
3.3 Results ................................................................................................................................................ 39 
3.4 Discussion .......................................................................................................................................... 41 
REFERENCES ............................................................................................................................................. 44 
4.1 Bone Phenotype of TLR5KO mice ...................................................................................................... 47 
4.2 Bone mechanical properties of PTH treated osteoporotic sheep ..................................................... 48 
4.3 Synthesis ............................................................................................................................................ 48 
REFERENCES ............................................................................................................................................. 49 
APPENDIX.................................................................................................................................................. 50 
Body mass adjusted TLR5KO bone size and mechanical properties ....................................................... 50 
REFERENCES ............................................................................................................................................. 52 
 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
1.1 Bone  
Bone is a hierarchical composite material with components consisting of mineral, organic 
molecules and water. At the millimeter scale, we observe two types of bone: cortical and 
trabecular (cancellous) bone (Fig. 1.1).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: In long bones such as the femur shown, trabecular and cortical bone are found. 
Femur length is measured from the lateral condyle to the greater trochanter. 
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 Cortical bone is the dense (5-10% porosity) outer shell and shaft of long bones such as 
the femur. Trabecular bone is much more porous than cortical bone and is located in the ends of 
long bones and the majority of the vertebra. The trabeculae of cancellous bone generally align 
with the directions of principal stress.  
1.2 Fragility Fracture and Whole Bone Mechanical Properties 
A fracture caused by a low level trauma such as a fall from standing height is known as a 
fragility fracture [1]. Clinically, bone mineral density (BMD), measured using dual-energy X-ray 
absorptiometry (DXA), provides an estimate of fracture risk. An increase in BMD is associated 
with a decrease in fracture risk; however, there are populations in which fracture risk exceeds 
what is expected from BMD. To understand fracture risk not explained by BMD, we can assess 
whole bone mechanical properties. Whole bone mechanical properties are determined by bone 
morphology and tissue material properties [2].  
Bone morphology refers to the shape of the bone.  The diaphysis of long bones consists 
of cortical bone. Cortical bone in the diaphysis can be characterized by measures of total area, 
marrow area and moment of inertias [3]. Total area is the area enclosed by the periosteum. 
Marrow area is the area enclosed by the endosteum. Moment of inertia is generally measured 
about the medial-lateral axis and anterior-posterior anatomical axes (Fig. 1.2A), and their ratio 
describes the ellipticity of the cross section.  Cortical area is a measure of bone mass 
accumulation. Trabecular bone has a complex microstructure that is most often defined by the 
bone volume fraction (BV/TV), although other measures of microstructure are also available 
(Fig 1.2B). 
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Bone tissue material properties are determined by the overall composition of bone and 
biophysical properties of the components [4]. The relative amounts of mineral, organic matrix 
(collagenous and non-collagenous proteins) and water influence bone tissue material properties. 
The size and shape of the mineral crystals and the type and degree of cross-linking of collagen 
fibrils are biophysical properties that are associated with whole bone mechanical properties [4].  
1.3 Bone Growth and Development 
The majority of our bones are generated during growth (ages 0-16 years). Bone growth 
involves increases in size, increases in degree of mineralization and changes to bone external and 
internal morphology [5]. Longitudinal bone growth occurs at the growth plates through a well 
described process known as endochondral ossification. Endochondral ossification occurs through 
a process of cartilage synthesis and subsequent replacement of cartilage by bone (Fig. 1.3A). 
Changes in cross sectional geometry occur as a result of intramembranous ossification where 
bone is formed on the periosteum and is resorbed on the endosteum (Fig. 1.3B).  
 
 
 
Figure 1.3: Examples of (A) cortical and (B) trabecular bone analyzed for bone morphology. re 1.2: Examples of (A) cortical and (B) trabecular bone analyzed for bone 
morphology. 
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Even after skeletal maturity is reached, bone is not a static organ. Bone remodeling is 
constantly altering bone shape. Bone remodeling is an orchestrated process of bone resorption 
and subsequent bone formation in the same location [6]. Newly formed bone undergoes a 
mineralization process and reaches 70% of its total mineralization a few days after being formed. 
1.4 Understanding Fracture Risk  
We are interested in understanding the causes of fracture risk. We can mimic human 
disease in animals using surgeries, alterations to the diet or by looking at genetic models. To 
determine how an experimental perturbation affects bone phenotype, we look at changes to bone 
morphology and mechanical performance.  
1.4.1 Mechanical Properties of Cortical Bone 
Cortical bone in the diaphysis is commonly evaluated in mouse models of bone disease. 
Although bone morphology can be determined using histology and gross measurements, 
microcomputed tomography (μCT) is the current standard for assessing bone structure in mice. 
Images of the mouse bone collected with μCT are submitted to image processing steps to 
separate the mineralized bone tissue from background and quantify bone mass and distribution. 
Figure 1.4: Depiction of the two types of bone growth is shown. (A) Endochondral ossification is shown where 
cartilage cells divide and grow before being replaced with bone tissue increasing the length of the bone, and (B) 
Intramembranous ossification is shown where bone is formed on already existing bone and bone is resorbed. 
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Common morphological parameters analyzed include bone length, total area, marrow area, 
cortical area and moment of inertia.  A region representing 2.5% of the bone length centered 
halfway along the length of the bone is used to analyze cross-sectional geometry associated with 
whole bone bending [7]. 
 The small size of mouse bones makes examining machined specimens of controlled 
shape challenging. For this reason, the most common biomechanical assessment of mouse bone 
is bending tests applied to a long bone, most often the femur (Fig.1.4).  
 
 
 
 
  
 
 
 
 
 
 
Whole bone mechanical properties of interest are peak load, stiffness and post yield 
displacement. A regression line with a slope representative of a 10% loss in stiffness starting at 
the beginning of the linear region intersects with the load-displacement curve at the yield point.  
 Peak moment (Mmax) relates to tissue material strength in bending (σb) by the following 
equation (Eq. 1.1): 
Figure 1.5: Femurs tested in three-point bending to determine mechanical properties. Top crosshead loads the bone at a 
rate of 0.1 mm/s until failure. The corresponding free body diagram is shown.  
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Mmax  =  σb ∗
I
c
      (1.1) 
for which 
I
c
 are the key geometric parameters relating applied load to tissue stress. To avoid 
making assumptions about femur geometry, we can plot peak moment against 
I
c
 and differences 
in regression lines can be attributed to an effect of the perturbation on tissue material properties. 
1.4.2 Mechanical Properties of Cancellous Bone  
Cancellous bone has a more complex microstructure than cortical bone and is challenging 
to evaluate mechanically. Methods of mechanically testing cancellous bone that provide 
boundary conditions to reduce systemic and random errors in compression tests were established 
in the 1990s [8]. The method involves press fitting cancellous bone cores into brass endcaps 
(Loctite 406 Prism Instant Adhesive, Applied Industrial Technologies, MA4230111). An 
extensometer is attached to the endcaps to measure displacement (Fig. 1.5). The specimen is 
loaded in displacement control. 
 
 
 
 
 
 
 
 
 
Figure 1.6: Cancellous cores tested in compression for which the sample is first 
preconditioned to reduce hysteresis before load is ramped to a predetermined strain   
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Stress and strain are calculated from the load and displacement data using the diameter 
(ф) of the core and the effective length (Leff). Leff is calculated as the exposed length plus half the 
length in the endcaps. The results of interest are Young’s modulus, yield stress and strain, 
ultimate stress and strain and toughness. The yield point is determined using the 0.2% offset 
method. Bone volume fraction and tissue material properties influence these structural properties 
in monotonic compression loading.  
1.5 Obesity and Bone  
  Obesity has traditionally thought to be beneficial for bone health as heavier individuals 
apply greater loads to their bones, resulting in greater bone mass. However, obesity has been 
associated with increases in fracture risk that is not explained by associated changes in bone 
mineral density [9]. Animal models of obesity have been used to study the effect of obesity on 
bone mass and mechanical properties.  
 Animal models of obesity include high fat diet (HFD), leptin receptor deficient (db/db) 
and leptin deficient (ob/ob) mice. The HFD mouse bone phenotype is characterized by reduced 
trabecular bone mass and impaired cortical bone tissue material properties [10, 11]. There has 
been conflicting results of the effect of leptin deficiency and leptin receptor deficiency on bone 
mass [12, 13]. These animal models exhibit severe obesity that can lead to symptoms of type 2 
diabetes. Animal models of obesity do not mimic more common levels of obesity seen in 
humans.   
1.6 Osteoporosis and PTH Therapy 
 Osteoporosis is a metabolic bone disease characterized by severe bone loss and is 
diagnosed by a low BMD score compared to that of a healthy 30 year-old. Osteoporosis is 
associated with increased risk of fragility fracture. Drug treatments are used to reverse the bone 
loss and reduce fracture risk in people with osteoporosis. Pharmaceuticals used to treat 
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osteoporosis are classified as either anti-resorptive or anabolic. Anti-resorptive drugs work by 
decreasing rates of bone resorption resulting in decreased bone remodeling and increased BMD. 
Anabolic agents work by increasing bone formation. Both classes of drugs have been shown to 
decrease fracture risk in osteoporotic patients [14, 15]. 
 Parathyroid hormone (PTH) is an example of an anabolic agent used to treat osteoporosis. 
PTH therapy works by increasing bone formation by stimulating bone remodeling [16]. 
Clinically and in small animal models PTH treatment increases bone mass and improve 
mechanical properties.  
1.7 Objective 
The objective of this thesis was to characterize the mechanical properties of cortical bone 
in a mouse model of metabolic syndrome and of cancellous bone in a sheep model of osteopenia. 
These two animal models mimic two populations of people for whom we are interested in 
understanding their risk of fragility fracture.  
1.7.1 Aim 1  
Obesity is a common precursor to metabolic syndrome [17]. The increased risk of 
fragility fracture associated with obesity may also be associated with metabolic syndrome. 
Metabolic syndrome is the presence of three or more of the following metabolic disorders: 
abdominal obesity, high triglycerides, low HDL-cholesterol, high blood pressure and high blood 
glucose [18]. Current animal models of obesity are not representative of the obesity levels 
associated with metabolic syndrome seen in humans. The toll-like receptor 5 deficient 
(TLR5KO) mouse displays metabolic syndrome with a more modest level of obesity and has 
been shown to have impaired cortical bone tissue material properties at 16 weeks in male mice 
[19]. The goal of this aim was to fully characterize the cortical bone phenotype of TLR5KO 
mice. Both male and female mice were used in this study and examined 10-55 weeks of age to 
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determine if age or sex modulated the effect of genotype. Changes to bone morphology and 
mechanical performance were assessed in the femoral mid-diaphysis by μCT and mechanical 
testing in three-point bending.  
1.7.2 Aim 2 
  Osteoporosis affects an estimated 200 million people worldwide and 8.9 million 
osteoporotic fractures occur per year [20]. Parathyroid hormone (PTH) is a treatment for 
osteoporosis that increases bone formation by stimulating bone remodeling.  The goal of this aim 
was to determine the effect of PTH treatment on mechanical properties of cancellous bone in 
compression in a sheep model of osteopenia. Osteopenia was induced in sheep (6-7 years old) 
via ovariectomy (OVX) and a diet to induce metabolic acidosis (MA). Osteopenia was developed 
over a year. The sheep were treated with either vehicle (n = 6) or PTH (n = 7) for a year. In this 
study, the monotonic mechanical properties of cancellous cores from the distal femur were 
determined.  
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CHAPTER 2 
BONE PHENOTYPE OF THE TOLL-LIKE RECEPTOR FIVE DEFICIENT MOUSE 
2.1 Introduction 
 Nine million people worldwide experience a fragility fracture a year [1]. A bone fracture 
that results from a low-level trauma such as falling from standing height is defined as a fragility 
fracture. To assess a person’s risk of a fragility fracture, bone mineral density (BMD) provides a 
snapshot of bone health. Low BMD is associated with an increased risk of fracture.    
Obesity is associated with increased fragility fracture risk that is not explained by 
changes in BMD. Mouse models are useful for studying disease mechanisms and testing the 
feasibility of interventions.  Mouse models of obesity that have been used to study bone include 
high fat diet (HFD), leptin deficient (ob/ob) and leptin receptor deficient (db/db). All three of 
these mouse models of obesity develop other metabolic abnormalities including insulin 
resistance, hyperglycemia and hypertension reminiscent of what is seen in humans  [3, 4]. High 
fat diet induces trabecular bone loss [5, 6] and conflicting results on cortical bone mass [5, 7-8]. 
HFD results in impaired cortical bone tissue material properties [7, 8] and reduced degree of 
mineralization [9] compared to wild type (WT). Leptin deficient mice have been reported to have 
increased [10, 11] and decreased [12-14] bone mass in the appendicular skeleton compared to 
WT. In the axial skeleton, leptin deficient mice have been reported to have increased trabecular 
bone mass [10-14] (Table 2.1). The large increase in adiposity (136-200% of WT body mass) of 
obesity models is representative of severe obesity. However, a large number of patients that are 
overweight but do not have severe obesity are diagnosed with metabolic syndrome. 
Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease (CVD) 
and type II diabetes (T2D) that include abdominal obesity, high triglycerides, reduced HDL-
14 
 
cholesterol, high blood pressure and high fasting glucose. An estimated 34% of the U.S. adult 
population meets the criteria for metabolic syndrome [2].  
Table 2.1: Mouse models of metabolic syndrome and bone phenotype are shown 
Model Traits of MetS 
% 
Increase 
in Body 
Mass 
Appendicular Skeleton Axial Skeleton  
TLR5KO 
[15, 18] 
Mild obesity 
Insulin resistance 
High blood 
pressure  
High blood 
glucose 
20% 
 
↓ Peak moment adjusted for 
geometry 
↑ Femoral total area and 
moment of inertia 
No effect on tibial 
cancellous bone mass 
No effect on TMD  
 
 
 
- 
 
HFD [5-9] 
Obesity 
Insulin resistance 
High blood 
glucose 
Hypertension 
30-55% 
↓Cancellous bone mass 
No effect on cortical bone 
mass 
↑ Cortical bone mass 
↓ Femoral bone mineral 
density 
↓Cortical bone material 
properties 
↓ Cancellous bone 
mass 
↓ Compressive max 
load 
↓Bone mineral 
density 
Leptin 
receptor 
deficient 
(db/db) 
[10, 11, 
13, 14] 
Obesity 
Insulin resistance 
High blood 
glucose 
70% 
 
↓ Trabecular bone volume 
fraction  
↓Cortical bone mass 
↑ Trabecular bone mass 
No effect on cortical bone 
↓ Decreased femoral max 
load 
 
↓Trabecular 
thickness 
↑Trabecular bone 
mass 
 
Leptin 
deficient 
(ob/ob) 
[10-12, 
14] 
Severe obesity 
Insulin resistance 
High blood 
glucose 
>100% 
 
↑Trabecular bone mass  
↓ Femur length, cortical 
thickness, mineral content 
and density and trabecular 
bone volume 
 
↑ Trabecular bone 
mass 
↑ Length, mineral 
content and density 
and trabecular bone 
volume 
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 The toll-like receptor 5 deficient  (TLR5KO) mouse is congenic mouse strain that 
displays metabolic syndrome with levels of obesity less (20% greater body mass than wild type)  
than that of other commonly used models (30-100% greater body mass than wild type) [15]. 
Toll-like receptor 5 (TLR5) is an innate immune receptor that recognizes flagellin [16]. 
TLR5KO mice fail to respond to flagellin resulting in alterations to the gut microbiome that lead 
to systemic and intestinal inflammation and a metabolic syndrome-like state characterized by 
mild obesity, insulin resistance, increased blood pressure and increased blood glucose [15, 17].   
Recently, TLR5KO mice were shown to have differences in bone mass and strength as 
compared to wild type controls [18]. Both the tibia and femur were analyzed in male mice at 16 
weeks. TLR5KO mice had greater femoral cortical bone total area and moment of inertia about 
the medial-lateral axis, but no differences were observed in peak load, stiffness and post yield 
displacement between TLR5KO and WT mice. The increased bone geometry with no differences 
in peak moment indicated impaired tissue material properties. No differences in cancellous bone 
mass and tissue mineral density of the tibia were observed between TLR5KO and WT.   
Sex [19] and age [20-22] are two factors known to influence bone mass and mechanical 
performance. Female mice bone size and mechanical properties are different than those of male 
mice even after adjusting for body size [19]. Bone size and material properties change rapidly 
until skeletal maturity is reached. Skeletal maturity is reached between 12 and 16 weeks in mice 
[21]. Differences in TLR5KO bone phenotype between male and female mice or during aging 
may indicate distinct mechanisms to explain the observed changes in bone mechanical 
performance.  
 The goal of the current study is to test the hypothesis that toll-like receptor 5 deficiency 
impairs cortical bone tissue material properties in both male and female mice.  Specifically, we 
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determined femur structure and strength in male and female TLR5KO mice at ages 10-55 weeks 
and compared the bone phenotype to that of WT controls. 
2.2 Material and Methods 
Under approval of the local IACUC, C57BL/6J and B6.129S1-Tlr5tm1Flv/J (TLR5KO) 
mice were acquired from Jackson and bred separately. The TLR5KO mouse is a congenic strain 
that has been backcrossed to the C57BL/6J background. The C57BL/6J is an appropriate WT 
control for TLR5KO [15, 23]. Animal were housed in plastic cages filled with ¼-inch corn cob 
bedding (The Anderson’ Lab Bedding, Ohio), provided a cardboard refuge environmental 
enrichment hut (Ketchum Manufacturing; Brockville, Ontario) and fed standard laboratory chow 
(Teklad LM-485 Mouse/Rat Sterilizable Diet) and water ad libitum. Female mice were 
euthanized at 10, 16 and 20 weeks of age and male mice were euthanized at 10, 16, 20 and 55 
weeks of age (n = 5-19/group, 201 total) (Table 2.2). The 16 week male mice were described in a 
prior work [18]. Epididymal fat pad mass and femora were collected after euthanasia. 
 
2.2.1 Cortical bone mechanical testing 
 Right femora were harvested, wrapped in PBS soaked gauze and stored at -20°C prior to 
analysis. Femoral length was measured from the greater trochanter to the lateral condyle. 
Microcomputed tomography (μCT) images of the femoral diaphysis were obtained with a voxel 
size of 25 μm (GE eXplore CT 120; 80 kVp, 32 μA, 100 ms integration time). Images were 
Table 2.2: Sample sizes are shown.  
Age (wks) 10 16 20 55 
 WT TLR5KO WT TLR5KO WT TLR5KO WT TLR5KO 
Male 
11 8 12 16 5 9 10 10 
Female 
13 7 8 19 9 19 - - 
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submitted to a Gaussian filter to remove noise, and a global threshold was used to segment 
mineralized bone from background. A region representing 2.5% of the femur length and centered 
midway between the greater trochanter and lateral condyle was used to determine femoral cross-
sectional geometry (total area, cortical area, marrow area and moment of inertia about the 
medial-lateral axis). After imaging, samples were stored frozen at -20C until mechanical testing. 
Femora were thawed at room temperature prior to mechanical testing and kept hydrated 
during testing.  Right femora were loaded in three point bending to failure at rate of 0.1 mm/s 
(858 Mini Bionix; MTS, Eden Prairie, MN, USA). Force was measured using a 100 lb load cell 
(Transducer Techniques, SSM-100, Temecula, CA), and displacement was measured using linear 
variable differential transducer at a 100 Hz sampling rate. 
 Stiffness was measured as the slope of the linear portion of the load displacement curve 
and adjusted for span length according to the following equation [24] (Eq. 2.1):    
S = (
P
y
) ∗
L3
48
   (2.1) 
where S is the bending rigidity, 
P
y
 is the unadjusted stiffness and L is the span length. Whole bone 
strength was evaluated as the maximum bending moment that could be applied to the bone. Peak 
bending moment was calculated as half the peak load times half the span length [24]. Femoral 
diaphyseal cross-sectional geometry and tissue material properties influence the peak moment as 
described by the following equation [25] (Eq. 2.2): 
M =  σb ∗
I
c
   (2.2) 
where σb is the tissue material strength in bending, I is the moment of inertia and c is the 
distance from the neutral axis to the bone surface. The parameter 
I
c
 represents the contribution of 
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cross-sectional geometry to peak moment. Differences in peak moment not explained by 
I
c
 can be 
attributed to differences in tissue material properties. 
2.2.2 Statistical Analyses 
Comparisons of bone geometry among mouse strains are commonly performed after 
adjustment for body size [24]. In this cohort, there were only weak associations between bone 
geometry within each group. For this reason, we analyzed raw (unadjusted) measures of bone 
geometry. All statistics were run separately for male and female mice. To determine if mouse 
strain influenced a bone size or mechanical property, we performed an analysis of covariance 
(ANCOVA), implemented with a generalized linear model (GLM) (Eq. 2.3).   
Parameter =  β0 + β1 ∗ Age + β2 ∗ Genotype + β3 ∗ Age ∗ Genotype    (2.3) 
The mean effect of genotype was calculated as 100 ∗
𝛽2
𝛽0
. A significant cross term indicated an 
age dependent effect of genotype. A one-way ANOVA was performed to test for differences 
between mouse strains at each age. Homogenous variance was tested using Levene's test and 
normality tested using the Shapiro-Wilk test.  
To determine if genotype affected whole bone bending strength in ways that were not 
explained by cross sectional geometry, we performed an ANCOVA, implemented with a GLM, 
with age and 
I
c
 as covariates and genotype as a fixed effect. Statistics were computed using JMP 
Pro (v.12, 2016; SAS Institute Inc., Cary, NC, USA) 
2.3 Results 
2.3.1 TLR5KO genotype 
Both male and female TLR5KO mice had increased body mass and epididymal fat pad 
mass compared to those of WT (Table 2.3). TLR5KO male mice had on average a 12.84% 
greater body mass and 93.89% greater epididymal fat pad mass than WT mice (p < 0.05, 
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determined from GLM coefficients, see Methods) (Fig. 2.1A-B). TLR5KO female mice had on 
average a 9.36% greater body mass and 88.60% greater epididymal fat pad mass than WT mice 
(Fig. 1.1C-D). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3: Body mass and fat pad mass of mice shown (Mean ± SD) 
 
Age 
(wks) 
10 16 20 55 
  WT TLR5KO WT TLR5KO WT TLR5KO WT TLR5KO 
M
al
e
 
Body 
weight 
(g) 
24.72 ± 
1.54 
26.76 ± 
2.48 
28.36 
± 1.03 
31.30 ± 
2.80 
28.40 ± 
1.93 
30.07 ± 
4.92 
36.21± 
2.67 
49.21 ± 
7.10 
Fat pad 
mass (g) 
0.37 ± 
0.056 
0.43 ± 
0.10 
0.51 ± 
0.11 
0.77 ± 
0.31 
0.53 ± 
0.13 
0.92 ± 
0.49 
1.47 ± 
0.41 
2.53 ± 
0.56 
F
em
al
e
 
Body 
weight 
(g) 
19.31 ± 
1.39 
22.01 ± 
1.24 
22.35 
± 0.99 
24.17 ± 
3.86 
21.24 ± 
1.31 
26.18 ± 
4.37 
- - 
Fat pad 
mass (g) 
0.21 ± 
0.07 
0.29 ± 
0.11 
0.21 ± 
0.06 
0.70 ± 
0.53 
0.27 ± 
0.08 
0.91 ± 
0.56 
- - 
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2.3.2 Whole bone mechanical performance 
TLR5KO mice showed reduced whole bone bending strength after accounting for age 
and 
I
c
 (Eq. 2.4). The effect of genotype was observed in both male and female mice (Table 4). 
The peak moment of bones from TLR5KO male mice were, on average, 10.09% less than WT 
after taking into account age and 
I
c
 (p < 0001,100* 
𝛽3
𝛽0
 from Eqn. 2.4 below). The peak moment of 
Figure 2.1: TLR5KO male and female mice had elevated body mass and fat pad mass compared to WT. (A) Body 
mass and (B) fat pad mass of male mice are shown. (C) Body mass and (D) fat pad mass of female mice are 
shown. 
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bones from TLR5KO female mice were, on average, 9.74% less than WT after taking into 
account age and 
I
c
 (p < 0.05).  
Mmax =  β0 + β1 ∗
I
c
+ β2 ∗ Age + β3 ∗ Genotype + β4 ∗
I
c
∗ Age + β5 ∗
I
c
∗ Genotype  (2.4)   
 
Differences in peak moment were also observed within each age group. The peak 
moment of bones from the TLR5KO male mice at 16 weeks was 10.70% less than that of WT 
after taking into account 
I
c
. At 16 weeks, the peak moment of bones from the TLR5KO female 
mice was 9.49% less than that of WT after accounting for 
I
c
 (Fig. 2.2). Reduced whole bone 
bending strength after taking account 
I
c
 was seen at most ages (Table 2.5). Differences in peak 
moment after accounting for 
I
c
 between WT and TLR5KO ranged from 9 to 21%.  
 
 
 
 
 
 
 
 
 
Table 2.4: Significant effects in multivariate linear regression of peak moment (Eq. 2.4) are 
shown. 
 I/c Age Genotype I/c*Age I/c*Genotype 
Peak moment 
(Male) 
p < 0.0001 p < 0.0001 p < 0.0001 p = 0.0063 p = 0.001 
Peak moment 
(Female) 
p < 0.0001 p < 0.0001 p < 0.05 NS NS 
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Figure 2.2: Whole bone bending strength is less in TLR5KO mice compared to that of WT 
after accounting for 
𝐈
𝐜
 (visualized as the differences between blue and red lines). The effect 
of genotype was seen in both male (solid lines) and female mice (dashed lines). 
9.49% 
 
10.70% 
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2.3.3 Femoral cross-sectional geometry 
Genotype, on average, had no effect on total area in male or female mice (Fig. 2.3). 
TLR5KO male mice had, on average, 3.47% greater marrow area compared to WT (p < 0.05, 
determined from GLM coefficients, see Methods). Genotype was not associated with differences 
in cortical area in male mice. There were no differences in marrow area between TLR5KO and 
WT female mice. TLR5KO female mice had, on average, a 3.11% greater cortical area than WT 
(p < 0.05). Moment of inertia about the medial-lateral axis of TLR5KO female mice was on 
average 3.97% greater than WT (p < 0.05) (Fig. 2.4B). Moment of inertia, on average, was not 
different between TLR5KO and WT male mice (Fig. 2.4A). There was no effect of genotype on 
femur length in male or female mice. 
Table 2.5: TLR5KO mice showed reduced mean peak bending moment after accounting 
for 
I
c
 in most of the age groups. (Mean  SD).   
 Male Female 
Age 
(wks) 
WT TLR5KO 
% 
Difference 
WT TLR5KO 
% 
Difference 
10 
38.54  
1.12  
34.94*  
0.93 
-9.55 
25.89  
1.17 
 
22.11*  
1.27 
  
-13.96 
16 
43.56  
0.84 
 
38.96*  
0.61 
 
-10.70 
35.19  
0.85 
 
31.85*  
0.52  
 
-9.49 
20 
38.98  
0.71 
38.98  
0.71 
0 
36.71  
0.45 
 
36.71  
0.45 
 
0 
55 
35.71  
1.27 
 
28.05*  
1.27  
 
-21.47 - - - 
* different from WT (p < 0.05) 
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The effect of genotype on cross-sectional geometry depended on the age and sex of the 
mice (Table 2.6). Total area of male TLR5KO mice at 16 weeks was greater than that of WT. 
Marrow area and cortical area were not different between TLR5KO and WT after taking into 
account total area at 10, 16 and 20 weeks (Eqn. 2.5). At 55 weeks, there was an effect of 
genotype on marrow area and cortical area after taking into account total area (p < 0.05, 100* 
𝛽2
𝛽0
 
from Eqn. 2.5 below). Marrow area was on average 22.12% greater and there was an equal 
reduction in cortical area of TLR5KO male mice at 55 weeks compared to WT after taking into 
account total area.  
 
Marrow or Cortical Area
=  β0 + β1 ∗ Total Area +  β2 ∗ Genotype + β3 ∗ Total Area ∗ Genotype (2.5) 
 
 
 
 
Figure 2.3: At 16 weeks of age, TLR5KO male mice have greater total area than that of WT. No 
differences in total area were observed between WT and TLR5KO at other ages in (A) male 
mice or (B) female mice.  
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Table 2.6:  Femoral diaphyseal cortical bone morphology is shown. (Mean ± S.D). 
   Age (wks) 10 16 20 55 
  WT TLR5KO WT TLR5KO WT TLR5KO WT  TLR5KO 
M
al
e
 
Femur 
length (mm) 
15.47 ± 
0.26 
15.43 ± 
0.22 
16.05 ± 
0.21 
15.88 ± 
0.26 
15.82 ± 
0.08 
15.77 ± 
0.34 
16.10 ± 
0.21 
15.94 ± 
0.33 
Total area 
(mm2) 
1.83 ± 
0.20 
2.05 ± 
0.20 
1.93 ± 
0.13 
2.13* ± 
0.17 
2.06 ± 
0.11 
1.86 ± 
0.18 
2.39 ± 
0.15 
2.37 ± 
0.15 
Marrow 
area (mm2) 
1.05 ± 
0.10 
1.21 ± 
0.10 
1.06 ± 
0.07 
1.17* ± 
0.15 
1.18 ± 
0.08 
1.07 ± 
0.10 
1.40 ± 
0.14 
1.48 ± 
0.12 
Cortical 
area (mm2) 
0.78 ± 
0.14 
0.83 ± 
0.14 
0.87 ± 
0.07 
0.96* ± 
0.08 
0.87 ± 
0.05 
0.79 ± 
0.09 
0.99 ± 
0.11 
0.89* ± 
0.07 
Moment of 
Inertia 
(mm4) 
0.13 ± 
0.03 
0.16 ± 
0.03 
0.15 ± 
0.02 
0.18* ± 
0.03 
0.16 ± 
0.03 
0.13 ± 
0.03 
0.21 ± 
0.03 
0.19 ± 
0.03 
F
em
al
e
 
Femur 
length (mm) 
14.85 ± 
0.38 
15.07 ± 
0.17 
15.63 ± 
0.13 
15.46* ± 
0.31 
15.59 ± 
0.60 
15.72 ± 
0.25 
- - 
Total area 
(mm2) 
1.51 ± 
0.12 
1.60 ± 
0.079 
1.53 ± 
0.07 
1.54 ± 
0.11 
1.52 ± 
0.13 
1.56 ± 
0.11 
- - 
Marrow 
area (mm2) 
0.90 ± 
0.06 
0.94 ± 
0.02 
0.89 ± 
0.08 
0.88 ± 
0.08 
0.85 ± 
0.06 
0.85 ± 
0.09 
- - 
Cortical 
area (mm2) 
0.61 ± 
0.07 
0.66 ± 
0.08 
0.63 ± 
0.03 
0.66 ± 
0.06 
0.66 ± 
0.08 
0.71 ± 
0.05 
- - 
Moment of 
Inertia 
(mm4) 
0.09 ± 
0.02 
0.10 ± 
0.01 
0.09 ± 
0.01 
0.10 ± 
0.01 
0.09 ± 
0.02 
0.10 ± 
0.01 
- - 
* different from WT (p < 0.05) 
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2.3.4 Mechanical performance 
No effect of genotype on mechanical properties of female mice was observed. There was 
no effect of genotype, on average, on mechanical properties of male mice. In male TLR5KO 
mice, there were differences in mechanical properties at 20 and 55 weeks (Fig. 2.5). Peak 
moment of 55-week-old male TLR5KO mice was less than that of WT. Bending rigidity was 
reduced and post yield displacement was increased at 20 and 55 weeks in TLR5KO male mice 
compared to those of WT (Table 2.7).  
 
 
 
 
Figure 2.4: Moment of inertia is greater in TLR5KO male mice at 16 weeks compared to that of 
WT. No differences between WT and TLR5KO were observed in (A) male mice at 10, 20 or 55 
weeks or in (B) female mice. 
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Figure 2.5: Mechanical properties of male (A-C) and female mice (D-F) are shown. (D-F) No differences were 
observed in peak moment, bending rigidity or post yield displacement between TLR5KO and WT female mice. 
(A) Peak moment was reduced in TLR5KO male mice at 55 weeks of age compared to that of WT. (B, C) 
Bending rigidity was reduced and post yield displacement was increased in TLR5KO male mice at 20 and 55 
weeks of age compared to those of WT. No differences in peak moment, bending rigidity or post yield 
displacement were observed between TLR5KO and WT in male mice at 10 or 16 weeks of age. 
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2.4 Discussion 
In this study, we investigated the effects of metabolic syndrome on bone mechanical 
performance in male and female mice at multiple age points. The TLR5KO bone phenotype is 
characterized by differences in bending strength that are not explained by geometry, suggesting 
impaired cortical bone tissue material properties compared to those of WT. Evidence of impaired 
cortical bone tissue material properties in TLR5KO mice compared to those of WT was detected 
in male and female mice. Cross-sectional geometry and tissue material properties determine 
whole bone bending strength.  
The geometric parameter 
I
c
 describes the geometric contribution to whole bone bending 
strength. As expected, there was a significant positive correlation between peak moment and 
I
c
 
Table 2.7: Differences between TLR5KO and WT in mechanical properties only at 20 and 55 weeks in male 
mice. (Mean ± S.D). 
 
Age (wks) 10 16 20 55 
 WT TLR5KO WT 
 
TLR5KO 
 
WT TLR5KO WT  TLR5KO 
M
al
e
 
Peak moment 
(Nmm) 
34.23 ± 
5.24 
37.70 ± 
6.94 
41.09 ± 
2.84 
40.47 ± 
3.00 
41.38 
± 4.27 
37.68 ± 
5.20 
36.24 ± 
4.22 
27.52 ± 
3.48 
Bending 
rigidity 
(Nmm2) 
642.16 
± 56.37 
813.40 ± 
234.25 
872.32 
± 
119.21 
877.06 ± 
170.39 
1142.6
5 ± 
99.85 
819.96* ± 
174.25 
1100.93 
± 
148.50 
924.76* 
± 152.91 
PYD 
(mm/mm2) 
0.15 ± 
0.05 
0.14 ± 
0.04 
0.10 ± 
0.040 
0.09 ± 
0.04 
0.05 ± 
0.04 
0.094* ± 
0.026 
0.041 ± 
0.041 
0.16* ± 
0.11 
F
em
al
e
 
Peak moment 
(Nmm) 
23.13 ± 
5.66 
23.66 ± 
2.49 
33.91 ± 
2.85 
32.35 ± 
3.29 
35.25 
± 4.63 
37.36 ± 
3.75 
- - 
Bending 
rigidity 
(Nmm2) 
569.03 
± 
157.11 
578.39 ± 
163.01 
858.22 
± 
203.63 
876.65 ± 
175.59 
949.65 
± 
185.90 
1070.77 ± 
204.04 
- - 
PYD 
(mm/mm2) 
0.27 ± 
0.15 
0.29 ± 
0.12 
0.07 ± 
0.05 
0.12* ± 
0.05 
0.07 ± 
0.04 
0.06 ± 
0.02 
- - 
* different from WT (p < 0.05) 
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across all groups. However, 
I
c
 alone did not explain the differences between genotypes at 10, 16 
and 55 weeks suggesting that TLR5KO mice have impaired bone tissue material properties. 
While differences in whole bone bending strength after taking into account cross-sectional 
geometry was detected at 10, 16 and 55 weeks, no differences were observed in 20 week mice. 
We attribute the lack of effect at 20 weeks to random chance.  
 Changes in bone geometry of TLR5KO mice compared to those of WT between 10 and 
20 weeks of age may be a mechanism employed by the skeleton to maintain whole bone bending 
strength despite impaired tissue material properties. Differences in bone geometry between 
TLR5KO and WT mice were dependent on the age and sex of the mice. At 55 weeks of age, 
TLR5KO male mice had reduced whole bone bending strength. There was reduced bone mass 
accumulation due to increased bone resorption on the inner surface than what would have been 
expected given the total area in TLR5KO male mice compared to that of WT.  
While there are many mechanisms for changing bone volume, only a few methods of 
changing bone tissue material properties in a mechanically relevant manner are known: 
alterations in tissue degree of mineralization, alterations in collagen cross-linking or collagen 
content, alterations in non-collagenous proteins and matrix bound water content. The degree of 
mineralization did not differ between the two mouse strains at 16 weeks of age in either female 
mice (ash fraction, data not shown) or male mice (TMD, measured with μCT) [18]. Other factors 
such as collagen and non-collagenous proteins may help explain the decreased whole bone 
strength after taking into account cross-sectional geometry in TLR5KO mice.  
 We did not observe differences in trabecular BV/TV of the tibial metaphysis between the 
TLR5KO and WT male mice at 16 weeks [18]. There were no differences in trabecular bone 
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mass between mouse strains in female mice (L5 vertebra, data not shown) or male mice (tibial 
metaphysis) [18].  
 Our findings in the TLR5 deficient mouse suggest that alterations in the gut microbiota 
can lead to changes in bone tissue material properties. Toll-like receptor 5 is the innate immune 
receptor for flagellin and does not have an endogenous ligand [17]. Hence, the phenotype of the 
TLR5KO mouse is caused primarily by alterations in host-microbe interactions. The TLR5KO 
phenotype does not develop in germ free mice (mice raised in absence of live bacteria) [15] and 
can be prevented by chronic antibiotics [18]. Additionally, the phenotype can be transferred to 
mice by transfer of the gut microbiota [15]. The gut microbiome may be directly or indirectly 
influencing the bone phenotype [26]. In the TLR5KO mouse, it is not clear if the associated 
alterations to the gut microbiome directly influence bone mechanical performance or if the 
microbiome induced metabolic-like syndrome causes the changes seen in bone mechanical 
performance.   
 There are a number of strengths of the current study. First, the TLR5KO mice exhibit 
metabolic syndrome with only mild obesity (108% - 135% of WT body mass) compared to other 
available obesity models (130% - 200% of WT body mass). Another strength of the current study 
is the examination of the relationship between bending strength and cross-sectional geometry. A 
majority of prior studies of mouse bone either report only whole bone mechanical properties 
(without addressing the role of geometry) or calculates tissue material properties using beam 
theory. The current approach not only accounts for geometry when comparing bone strength 
among mice but also does not require assumptions regarding beam theory. Secondly, we studied 
both male and female mice with an age range of 10 to 55 weeks old. Sex and age are two factors 
that are known to influence bone phenotype.   
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 There are some limitations that have to be considered. The current study is limited by not 
directly analyzing tissue material properties. Direct measures of tissue material properties could 
better explain the differences in mechanical performance; however, methods of assessing bone 
tissue material properties have their own limitations (see Supporting Information in Jepsen et. al. 
[24]). Secondly, the current study uses the C57BL/6J mice as control for the TLR5KO strain 
despite minor remnants of B6.129S1 strain. The TLR5KO congenic strain is backcrossed for 11 
generation of C57BL/6J to ensure 99.9% identical genetics to minimize the potential effects of 
B6.129S1.  
 Despite these limitations, the observation that metabolic syndrome associated with 
alterations to the gut microbiome can affect whole bone bending in ways that are not explained 
by cross-sectional geometry suggests that the microbiome and metabolic syndrome can alter 
bone tissue material properties. Bone tissue material properties are a recognized contributor to 
“bone quality” [27]. Bone quantity and quality determine risk of fracture [28]. At 10, 16 and 20 
weeks of age, changes in bone geometry maintained whole bone bending strength compared to 
that of WT despite impaired tissue material properties. However, at 55 weeks of age where bone 
mass accumulation due to increases in endosteal resorption was reduced in the TLR5KO mice 
compared to that of WT, whole bone mechanical properties were impaired. Changes in whole 
bone mechanical properties are often cited as a contributor of fracture risk that exceeds what is 
expected from BMD. Our findings in mice suggest that metabolic syndrome may contribute to 
the risk of fracture by impairing cortical bone tissue material properties. 
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CHAPTER 3 
EFFECT OF PTH-TREATMENT ON MECHANICAL PROPERTIES OF CANCELLOUS 
BONE 
3.1 Introduction 
Osteoporosis-related fractures are a significant clinical concern with 8.9 million people 
experiencing an osteoporotic fracture a year worldwide [1]. Anabolic agents can be used to treat 
osteoporosis by increasing bone formation. Parathyroid hormone (PTH) is an anabolic drug that 
is approved by the FDA to treat osteoporosis.  Patients with osteoporosis treated with PTH 
experience 9-13% increase in bone mineral density (BMD) of the lumbar spine and 3-6 % 
increase in BMD of the hip. Risk of vertebral fractures is reduced by 65-69% and risk of non-
vertebral fractures is reduced by 35-54% [2, 3].  
Small animal model studies have shown that intermittent treatment with PTH increases 
bone mass [4-9] and improves bone mechanical properties [10-13]. Assessment of the effect of 
PTH treatment on mechanical properties has been limited to the femoral neck [11] and vertebra 
[10, 12-13]. Large animal studies are needed to understand the effect of PTH treatment on 
cancellous bone mechanical performance. Monotonic and fatigue loading are necessary to fully 
characterize the effect of PTH treatment on mechanical performance of cancellous bone. Here, 
we focused on monotonic loading in compression. 
The goal of this study was to test the hypothesis that increased bone formation due to 
PTH treatment would improve mechanical performance of cancellous bone.  Specifically, we 
mechanically tested cancellous bone specimens from the right distal femur monotonically in 
compression from osteopenic sheep treated with PTH or vehicle. 
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3.2 Materials and methods 
 A sheep model of osteopenia was used in this study. Sheep were ovariectomized (OVX) 
at 6-7 years old and were kept on a metabolic acidosis (MA) diet to induce osteopenia. A year 
after OVX, sheep were treated with either vehicle (n = 6) or PTH (n = 7) for a year. Following 
euthanasia, femurs were collected and stored at -20⁰C. Cylindrical cores were cut using a 
diamond-tipped coring tool with a diameter of 7.5 mm (Starlite, Lancaster, PA, USA). 
3.2.1 Sample preparation 
 Cancellous bone cores were cut from the medial-caudal quadrant of the right distal femur 
aligned with the principal trabecular orientation and stored at -20C.  Specimens had an average 
height-to-diameter ratio of 2.43:1 (length: 17.90 ± 6.22 mm and diameter: 7.36 ± 0.06 mm). 
Marrow was removed from the ends of the cores using a low-pressure water jet. Cores were 
press-fit into brass endcaps (Loctite 406 Prism Instant Adhesive, Applied Industrial 
Technologies, MA4230111). Specimens were stored at 4C overnight to allow the glue to set 
before testing. 
3.2.2 Mechanical testing 
 Cancellous cores were loaded in compression. Specimens were brought to room 
temperature prior to testing. Load was measured using a 200 lb load cell (SSM-100, Transducer 
Techniques, Temecula, CA), and displacement was measured with a 25-mm gauge length 
extensometer attached to the brass endcaps. The cancellous cores were preconditioned for 10 
cycles at 1.25 Hz from 0 to 0.2% strain, and then the load was ramped to 3% strain at 0.5% 
strain/sec (858 Mini Bionix; MTS, Eden Prairie, MN, USA).  
Stress and strain were calculated from the load and displacement data. The mechanical 
properties of interest were Young’s modulus, yield stress and strain, ultimate stress and strain 
and toughness to ultimate. The yield point was determined based on the 0.2% offset method. 
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3.2.3 Microcomputed Tomography 
 Microcomputed tomography (μCT) images of cancellous specimens from the distal femur 
were obtained with a voxel size of 25 μm. Images were submitted to a Gaussian filter, and a 
global threshold was used to segment mineralized bone from background. The images of 
cancellous bone were used to determine bone volume fraction (BV/TV).   
3.3 Results 
 
No differences in mechanical properties in compression were detected between vehicle 
treated and PTH treated samples (Table 3.1). However, cancellous bone from PTH treated 
animals showed a trend towards increased Young’s modulus and yield and ultimate stress (Fig. 
3.1).  Yield and ultimate stress were correlated with Young’s modulus (p < 0.001). 
 
 
 
 
 
 
Table 3.1: Results of compression test. Mean ± SD. 
 Control (n=5) PTH (n=6) p-value 
Young’s modulus (MPa) 662.6 ± 312 839.3 ± 374 0.21 
Yield stress (MPa) 4.15 ±1.6 4.96 ± 2.1 0.24 
Yield strain (%) 0.86 ± 0.2 0.80 ± 0.1 0.26 
Ultimate stress (MPa) 5.38 ± 1.7 5.91 ± 1.9 0.32 
Ultimate strain (%) 2.32 ± 0.86 1.75 ± 0.66 0.13 
Total Toughness to Ult (kJ/m3) 91.15 ± 44.0 70.24 ± 20.1 0.18 
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We expected that increases in bone mass would improve mechanical properties of 
cancellous bone of PTH treated sheep compared to those of Control. However, the range in 
BV/TV across both groups was small, and no correlations were present between BV/TV and 
mechanical properties (Young’s modulus, yield strength and ultimate strength) (Fig. 3.2). 
Figure 3.1: The mean Young's modulus of PTH treated samples was 26.7% greater than 
control. However, with the sample sizes and variation, no significant differences were 
detected. 
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3.4 Discussion 
 In this study, we investigated the effect of treatment with PTH on the mechanical 
properties of cancellous bone in a sheep model of osteopenia. No detectable differences in 
uniaxial compression properties were observed. Mechanical properties are determined by bone 
mass and tissue material properties. Bone volume fraction (BV/TV) was not significantly 
different between groups. There may be differences in bone tissue material properties that are not 
detectable in monotonic compression but are in fatigue or fracture toughness. 
 Previous studies of the mechanical effects of PTH treatment in bone found improved 
mechanical properties in the femoral neck of rats [11] and lumbar vertebra of rats [10] and 
Figure 3.2: No correlation between Young's modulus and BV/TV. BV/TV in PTH-treated group 
was not different than that of the Control group. Accordingly, no differences in Young’s 
modulus between treatment groups were detected. 
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monkeys [12, 13]. The current study looked at cancellous bone from the distal femur in a sheep 
model of osteoporosis. We found that PTH treatment for the time period studied did not affect 
cancellous bone mass or mechanical properties in uniaxial compression. The effects of PTH 
treatment on bone mass may be greater in other regions of the skeleton or if PTH treatment had 
been extended for a longer period of time.   
 The current study has a number of strengths. First, this study used a large animal model 
of osteoporosis. Large animal models have the advantage that cancellous bone can be 
mechanically characterized independently of cortical bone. Second, cancellous bone was tested 
not only in monotonic compression but also fatigue (data not shown). Both uniaxial and fatigue 
mechanical properties influence fracture risk. 
 Some limitations have to be considered. First, the bone volume fraction in the distal 
femur of osteopenic sheep, even with OVX + MA diet (0.18 – 0.35), was greater than that of 
older adults (0.10-0.15). In addition, the small sample size with the high variation in mechanical 
properties limited our ability to detect differences in uniaxial compression. 
 Despite these limitations, the lack of detectable effects of PTH treatment on mechanical 
properties of cancellous bone of the distal femurs contributes to the understanding of the effect 
of PTH treatment on bone. Bone mass and tissue material properties influence bone mechanical 
properties. There were no detectable differences in bone volume fraction between PTH treated 
and Control samples, and no detectable differences in mechanical properties in uniaxial 
compression. There may be differences in tissue material properties of PTH treated compared to 
Control that are not highly influential in monotonic loading; however, can play a role in 
properties in fatigue or fracture toughness. 
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Fracture risk is influenced by more than compressive strength. Fatigue and fracture 
toughness influence fracture risk and can provide explanations for fracture risk not explained by 
BMD [14]. Compressive strength measures the maximum load the bone tissue can withstand at 
any single time. However, bone is cyclically loaded and accumulates damage daily. Fracture 
toughness determines the maximum load a bone can withstand with damage present.  Only 41% 
of vertebral fragility fractures can be explained by a single traumatic event [15]. Therefore, the 
spectrum of mechanical properties must be considered to capture the full picture of how resistant 
bone is to fracture.   
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CHAPTER 4 
SUMMARY AND DISCUSSION 
Fragility fractures are associated with high morbidity. An estimated 9 million people 
worldwide suffer from a fragility fracture each year. Some populations have increased risk of 
fragility fractures. Obesity is associated with increased risk of fragility fracture that is not 
explained by BMD. Obesity is a common precursor for metabolic syndrome; therefore, 
metabolic syndrome may contribute to increased risk of fracture. Osteoporosis is a metabolic 
bone disease that is associated with high risk of fragility fractures. PTH is an anabolic drug to 
treat osteoporosis and reduce the risk of fracture. Here, I characterized the bone phenotype of the 
TLR5KO mice and determined the effect of PTH treatment on mechanical properties in 
compression of cancellous bone in a sheep model of osteopenia.   
4.1 Bone Phenotype of TLR5KO mice 
 We characterized the bone phenotype of the TLR5KO mice. We found that the TLR5KO 
was characterized by impaired cortical bone tissue material properties compared to those of WT. 
Male and female TLR5KO mice both exhibited this phenotype. There were age and sex 
dependencies on the effect of mouse strain on appositional growth. Whole bone mechanical 
strength is known to contribute to resistance to fracture [1]. Whole bone mechanical strength is 
determined by bone morphology and tissue material properties. At 10, 16 and 20 weeks, bone 
morphology of the TLR5KO mice compensated for the impaired tissue material properties to 
maintain whole bone bending strength compared to that of WT. However, at 55 weeks, whole 
bone bending strength of TLR5KO mice was reduced compared to that of WT.  Bone mass 
accumulation in the TLR5KO male mice at 55 weeks is reduced compared to that of WT due to 
increased endosteal resorption. These findings suggest that metabolic syndrome may provide an 
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explanation of why some populations of people have increased risk of fracture beyond what 
would be expected given BMD. 
4.2 Bone mechanical properties of PTH treated osteoporotic sheep 
 We tested the effect of PTH treatment on cancellous bone mechanical properties in 
compression. The mean Young’s modulus of PTH treated sheep was 26.7% greater compared to 
WT. There was no effect of treatment detected in the cancellous bone from the distal femur 
mechanical properties in monotonic compression possibly due to the small sample size and high 
variation. In the larger study, treatment affected cancellous bone mechanical properties in 
fatigue. Both monotonic and fatigue properties influence fracture risk. 
4.3 Synthesis 
The objective of this work was to assess the mechanical properties of cortical bone in a 
mouse model of metabolic syndrome and cancellous bone in a sheep model of osteopenia. The 
toll-like receptor 5 deficient (TLR5KO) mouse is a novel model of metabolic syndrome. The 
metabolic syndrome in TLR5KO mice developed as a result of alterations to the gut microbiome. 
In Aim 1, we found that TLR5KO mice had impaired cortical bone tissue material properties 
compared to that of WT. The use of a sheep model of osteopenia helps fill the need for large 
animal studies in characterizing the effect of PTH treatment on mechanical properties of 
cancellous bone. Although no significant differences were detected in monotonic compression 
loading of cancellous bone, there was an effect of treatment on the fatigue mechanical properties 
of cancellous bone. 
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APPENDIX 
 
Body mass adjusted TLR5KO bone size and mechanical properties 
 Bone geometry parameters are often adjusted for body size to account for differences in 
body size between mouse strains. Combining data from male and female mice or mice of 
different ages is not recommended [1]. Body mass adjustments were performed separately for 
each age/sex pair using the following equation (Eq. 1). 
 
Adjusted Bone traitijkl = Bone traitijkl − Slope of Bone Trait with Body Massijk ∗
(Body Massijkl − Average Body Massijk)      (1)  
 
in which i is the sex, j is the age, k is the genotype and l refers to a specific mouse. Average body 
mass was calculated as the average of the mean body masses of WT and TLR5KO mice to avoid 
bias due to differences in sample size.  
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Femoral diaphyseal cortical bone morphology is shown. All values have been adjusted for body mass. (Mean 
± S.D). 
   Age (wks) 10 16 20 55 
  WT TLR5KO WT TLR5KO WT TLR5KO WT TLR5KO 
M
al
e
 
 
Femur 
length (mm) 
15.59 ± 
0.10 
15.37* ± 
0.15 
16.22 ± 
0.18 
15.83* ± 
0.22 
15.81 ± 
0.08 
15.72 ± 
0.22 
16.28 ± 
0.19 
15.82* ± 
0.30 
Total area 
(mm2) 
 
1.95 ± 
0.13 
1.97 ± 
0.05 
1.98 ± 
0.12 
2.12* ± 
0.17 
2.10 ± 
0.04 
1.83* ± 
0.11 
2.46 ± 
0.15 
2.28* ± 
0.11 
Marrow 
area (mm2) 
1.08 ± 
0.09 
1.17 ± 
0.06 
1.11 ± 
0.06 
1.17 ± 
0.15 
1.21 ± 
0.03 
1.05 ± 
0.06 
1.41 ± 
0.14 
1.40 ± 
0.09 
Cortical 
area (mm2) 
0.86 ± 
0.07 
0.79 ± 
0.09 
0.87 ± 
0.07 
0.94 ± 
0.06 
0.89 ± 
0.03 
0.78 ± 
0.06 
1.05 ± 
0.10 
0.87* ± 
0.07 
Moment of 
Inertia 
(mm4) 
0.15 ± 
0.02 
0.14 ± 
0.01 
0.15 ± 
0.02 
0.17* ± 
0.03 
0.17 ± 
0.01 
0.12* ± 
0.02 
0.22 ± 
0.03 
0.17* ± 
0.02 
F
em
al
e
 
Femur 
length (mm) 
15.07 ± 
0.21 
15.06 ± 
0.17 
15.72 ± 
0.09 
15.43* ± 
0.28 
16.57 ± 
0.29 
15.73* ± 
0.25 
- - 
Total area 
(mm2) 
1.58 ± 
0.08 
1.54 ± 
0.03 
1.52 ± 
0.07 
1.53 ± 
0.09 
1.70 ± 
0.09 
1.52 ± 
0.09 
- - 
Marrow 
area (mm2) 
0.94 ± 
0.04 
0.93 ± 
0.02 
0.88 ± 
0.08 
0.87 ± 
0.06 
0.93 ± 
0.05 
0.82 ± 
0.07 
- - 
Cortical 
area (mm2) 
0.64 ± 
0.05 
0.61 ± 
0.05 
0.64 ± 
0.02 
0.66 ± 
0.06 
0.77 ± 
0.05 
0.70 ± 
0.05 
- - 
Moment of 
Inertia 
(mm4) 
0.10 ± 
0.01 
0.09 ± 
0.01 
0.09 ± 
0.004 
0.09 ± 
0.01 
0.11 ± 
0.01 
0.10* ± 
0.01 
- - 
* different from WT (p < 0.05) 
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